Summarized by Masters of Longevity from Longevity Technology.
Retro Biosciences’ update describes a biotech trial dosing adjustment and enrollment expansion; readers will get a concise look at why the company changed course.
Key Takeaways
- Retro Biosciences is increasing RTR-242 trial enrollment from 76 to 108 participants by adding two new cohorts.
- Early Phase 1 dosing produced no major safety signals, prompting higher doses to seek pharmacodynamic effects.
- RTR-242 targets lysosomal acidity to boost autophagy as a proposed approach to address neurodegeneration.
